Reading on the web. Open in the Thier app for the full interactive version, progress tracking, and XP.
Open

GLP-1 Trade-offs

1-minute read 30 XP in app 6 cards

Every lever moves more than one thing

GLP-1s are not a free lunch. The mechanisms that cause the weight loss also drive the downsides. Knowing them before you start lets you plan around them — most are manageable, some are hard limits.

Fact

Muscle loss is real

In STEP 1, about 40% of the total weight lost on semaglutide was lean mass. This is roughly on par with diet-only weight loss — not worse — but still meaningful. Prioritising protein (1.6–2.2 g/kg) and resistance training while on a GLP-1 preserves the lean tissue you want to keep.

~40% of weight lost is lean mass
Fact

Bone mineral density concerns

Whenever you lose significant weight fast, BMD can drop. GLP-1 trials show small but measurable reductions in hip and spine BMD at year 1. The long-term fracture-risk implications aren't yet clear — but resistance training + adequate vitamin D + calcium help offset the loss.

True or false

True or False

If you stop a GLP-1, the weight stays off.

Stopping a GLP-1 keeps the weight off long-term
STEP 4 showed roughly two-thirds of weight lost comes back within a year of stopping semaglutide, if lifestyle changes aren't in place. These drugs are more like 'chronic therapy' than 'cycle-and-done.'
Fact

Side effects you should plan for

Nausea (20–40%), vomiting (~10%), constipation, early satiety. These cluster during the first 4–8 weeks and dose-titration period. Rarer but serious: pancreatitis, gallbladder disease, thyroid C-cell concerns (boxed warning). Extremely rare: non-arteritic ischaemic optic neuropathy (NAION) — a 2024 observational finding still being evaluated.

Takeaway

Key Takeaway

GLP-1s work. They also take lean mass, reduce BMD, produce GI symptoms, and usually require long-term use. The best users pair them with resistance training, high protein, and a plan for what happens at year 2.

References

  1. Body composition on semaglutide — STEP 1 DXA sub-studyWilding et al., 2022
  2. GLP-1 therapy and bone mineral density — meta-analysisZhang et al., 2021
  3. Semaglutide safety profile — pooled adverse event analysisRubino et al., 2022
  4. Semaglutide and NAION — retrospective JAMA Ophthalmology analysisHathaway et al., 2024

Track your progress

Read the cards above, then mark this lesson complete to track your progress.
Open in app for XP
Up next

GLP-1 Quiz